The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Bispecific BCMA-CD3 antibody teclistamab is efficacious and tolerable in R/R MM
Amrita Krishnan, MD, City of Hope National Medical Center, Duarte, CA discusses the results of a relapsed/refractory multiple myeloma (MM) trial (NCT03145181) of teclistamab, a bispecific BCMA-CD3 antibody that activates T-cell killing of BCMA-expressing MM cells. Subcutaneous (SC) and intravenous administration was investigated in the process of establishing a recommended Phase II dose. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
